7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC

Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In PAPILLON (NCT04538664), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo (median, 11.4 vs 6.7 months mo; HR, 0.40; 95% CI, 0.30–0.53; P0.05 for all). At 6 mo, 43% vs 25% of pts reported no dyspnea (P0.05), and 18% vs 8% reported no fatigue for ami-chemo vs chemo (P<0.02), respectively. Updated results will include data from PROMIS-PF 8c. Ami-chemo significantly prolonged time to symptomatic progression vs chemo. More pts in the ITT population reported improved or stable functioning and absence of lung cancer-related symptoms for ami-chemo vs chemo. The deeper tumor responses and improved disease control observed with ami-chemo corresponded with improved patient-relevant endpoints in first-line EGFR Ex20ins advanced NSCLC.